Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Treatment by BCG”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00023842
What this trial is testing

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 97
Testing effectiveness (Phase 2)Study completedNCT03672240
What this trial is testing

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC)
Asieris Pharmaceutical Technologies Co., Ltd. 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT04706598
What this trial is testing

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Who this might be right for
Urinary Bladder NeoplasmsImmunotherapy
Fudan University 25
Not applicableUnknownNCT06324058
What this trial is testing

Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC

Who this might be right for
Bladder Cancer
Huashan Hospital 190
Large-scale testing (Phase 3)Ended earlyNCT01200992
What this trial is testing

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder NeoplasmNeoplasm Recurrence, LocalTransitional Cell, Carcinoma+2 more
Bioniche Life Sciences Inc. 84
Not applicableAvailableNCT06443944
What this trial is testing

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Who this might be right for
Non-Muscle Invasive Bladder CancerUrothelial CarcinomaUrologic Cancer+1 more
CG Oncology, Inc.
Large-scale testing (Phase 3)UnknownNCT06241755
What this trial is testing

Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Non-Muscle Invasive Bladder Cancer
Chengdu CoenBiotech Co., Ltd 412
Large-scale testing (Phase 3)UnknownNCT00052156
What this trial is testing

Vaccine Therapy for Patients With Stage IV Melanoma

Who this might be right for
Malignant Melanoma
CancerVax Corporation 670
Not applicableStudy completedNCT01007058
What this trial is testing

Markers of Response to Intravesical Bladder Cancer Therapy

Who this might be right for
Bladder Cancer
M.D. Anderson Cancer Center 150
Early research (Phase 1)Study completedNCT01498172
What this trial is testing

BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Bladder Cancer
Patrice Jichlinski 23
Testing effectiveness (Phase 2)Study completedNCT00234039
What this trial is testing

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

Who this might be right for
Bladder Cancer
SWOG Cancer Research Network 58
Early research (Phase 1)WithdrawnNCT04109092
What this trial is testing

Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Who this might be right for
Urinary Bladder Neoplasms
Eisai Inc.
Testing effectiveness (Phase 2)Ended earlyNCT01118351
What this trial is testing

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Who this might be right for
Recurrent Bladder CancerTransitional Cell Carcinoma of the Bladder
Case Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Ended earlyNCT02625961
What this trial is testing

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 296
Early research (Phase 1)Study completedNCT03053635
What this trial is testing

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Theralase® Technologies Inc. 6
Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Not applicableEnded earlyNCT06026332
What this trial is testing

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Who this might be right for
Bladder Cancer
Ferring Pharmaceuticals 202
Early research (Phase 1)Study completedNCT03191578
What this trial is testing

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®

Who this might be right for
High-Risk Non-Muscle-Invasive Bladder Cancer
Archivel Farma S.L. 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT03504163
What this trial is testing

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Who this might be right for
Bladder Cancer
Memorial Sloan Kettering Cancer Center 45
Early research (Phase 1)WithdrawnNCT03552796
What this trial is testing

SEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaBladder Cancer Stage 0Bladder Cancer Stage I
University of Southern California
Next Page